Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:

Amgen Aranesp Price Is In Middle Of Procrit Range; Reimbursement Likely

  • News

Executive Summary

Amgen is launching the anemia agent Aranesp at a price falling in the middle of the range for Johnson & Johnson's erythropoietin brand Procrit.

You may also be interested in...



Aranesp Oncology Label Includes Emphasis On Longer Half-Life Than Procrit 

Aranesp labeling for chemotherapy-induced anemia includes increased emphasis on the product's less frequent dosing than epoetin alfa (J&J's Procrit)

Aranesp Oncology Label Includes Emphasis On Longer Half-Life Than Procrit 

Aranesp labeling for chemotherapy-induced anemia includes increased emphasis on the product's less frequent dosing than epoetin alfa (J&J's Procrit)

Amgen Ends Praecis Plenaxis Collaboration After FDA Requests More Studies

Praecis is planning additional studies on the prostate cancer treatment Plenaxis (abarelix) to evaluate switching non-responders to alternate therapies.

Table

View full table

Tags:
UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By